Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Short form equity change report name of listed company: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) place of stock listing: Shanghai Stock Exchange
Stock abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Stock Code: 688488
Information disclosure obligor: Shanghai LeYang Kairui enterprise management partnership (limited partnership) Company Address: room a1193, building 3, No. 112-118, Gaoyi Road, Baoshan District, Shanghai mailing address: room a1193, building 3, No. 112-118, Gaoyi Road, Baoshan District, Shanghai nature of share change: share reduction
Signed on: January 11, 2022
Statement of information disclosure obligor
1、 This report is prepared by the information disclosure obligor in accordance with the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies, the standards for the content and format of information disclosure by companies that publicly issue securities No. 15 – Report on changes in equity and other relevant laws and regulations.
2、 The information disclosure obligor has obtained necessary authorization and approval for signing this report, and its performance does not violate or conflict with any provision in the articles of association or internal rules of the information disclosure obligor.
3、 In accordance with the provisions of the securities law of the people’s Republic of China and the measures for the administration of the acquisition of listed companies, this report has fully disclosed the changes in the shares in which the information disclosure obligor has interests in Jiangsu Aidea Pharmaceutical Co.Ltd(688488) . As of the signing date of this report, except for the shareholding information disclosed in this report, the information disclosure obligor has not increased or reduced its shares in Jiangsu Aidea Pharmaceutical Co.Ltd(688488) by any other means.
4、 The information disclosure obligor has obtained necessary authorization and approval for signing this report, and its performance does not violate or conflict with any provision in the articles of association or internal rules.
5、 This equity change is based on the information stated in this report. Except for the information disclosure obligor, no unit or individual has been entrusted or authorized to provide information not listed in this report and make any explanation and explanation to this report.
6、 The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and will bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
catalogue
Section 1 interpretation Section 2 Introduction to information disclosure obligors Section III purpose of equity change Section IV equity change method 7 Section V Trading of listed shares in the first six months 8 section VI other major matters Section VII declaration of information disclosure obligor Section 8 documents for future reference 11 attached table brief report on changes in equity twelve
Section I interpretation
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) , the listed company, the public refers to Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Si LeYang Carey, and the information disclosure obligation refers to the person of Shanghai LeYang Carey enterprise management partnership (limited partnership)
This equity change refers to the reduction of shares held by the information disclosure obligor
This report and this report refer to Jiangsu Aidea Pharmaceutical Co.Ltd(688488) simplified equity change report
CSRC refers to the China Securities Regulatory Commission
Shanghai Stock Exchange and stock exchange refer to Shanghai Stock Exchange
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
Note: in this report, if the sum of the itemized values is inconsistent with the mantissa of the total, it is caused by rounding.
Section II introduction to information disclosure obligors
1、 Basic information of information disclosure obligor
As of the signing date of this report, the basic information of information disclosure obligors is as follows:
Company name: Shanghai LeYang Kairui enterprise management partnership (limited partnership)
Unified social credit code 91321000ma1mu912xf
Registered address: room a1193, building 3, No. 112-118, Gaoyi Road, Baoshan District, Shanghai
The registered capital is 62.32 million yuan
Executive partner Wang Guangrong
Date of establishment: September 12, 2016
Enterprise type: limited partnership
Business scope: general items: enterprise management; Enterprise management consulting; Information consulting service (excluding license)
Information consulting services). (except for the items that need to be approved according to law, they shall be approved according to law with their business license
Main business activities)
Business term: September 12, 2016 to September 7, 2036
Mailing address: room a1193, building 3, No. 112-118, Gaoyi Road, Baoshan District, Shanghai
2、 Basic information of directors and main responsible persons of information disclosure obligors
As of the signing date of this report, the basic information of the principal of the information obligation discloser is shown in the table below:
Name Gender Position nationality long-term residence have you obtained the right of residence in other countries or regions
Wang Guangrong, female executive partner, China no
3、 Shares of listed companies owned by information disclosure obligors
As of the date of signing this report, the information obligatory Discloser has no situation that the shares with interests in other listed companies in China have reached or exceeded 5% of the issued shares of the company.
Section III purpose of equity change
1、 Purpose of this equity change
The reason for this equity change is that the information disclosure obligor reduces its shares of the company based on its own capital needs. 2、 Increase or decrease plan of information disclosure obligor in the next 12 months
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) published the announcement of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) shareholders’ share reduction plan through centralized bidding (Announcement No.: 2021-051) on the designated information disclosure website on December 1, 2021. The information disclosure obligor plans to reduce the company’s shares by centralized bidding within 6 months after 15 trading days from the date of performing the obligation of pre disclosure of shares reduction, The proportion in the total share capital of the company shall not exceed 1%, and within any continuous 90 days, the total number of shares reduced through centralized bidding shall not exceed 4200000 shares, that is, not more than 1% of the total number of shares of the company. The specific reduction price will be determined according to the market price.
As of the signing date of this report, the above reduction plan of the information disclosure obligor has not been implemented.
In addition to the above matters, the information disclosure obligor does not rule out the possibility of increasing or continuing to reduce its shares in the listed company on the basis of complying with the current effective laws, regulations and normative documents. If the shares of the listed company held by the information disclosure obligor change in the future, the information disclosure obligor will timely perform the information disclosure obligations in accordance with relevant laws and regulations.
Section IV changes in equity
1、 Change mode of equity
The information disclosure obligor completes this equity change through centralized bidding trading and block trading. 2、 Details of the rights and interests of the information disclosure obligor
Before this equity change, the information disclosure obligor held 23632560 shares of the listed company, which were obtained before IPO, accounting for 5.626800% of the total share capital of the listed company.
After the equity change, the number of shares held by the information disclosure obligor in the listed company was reduced from 23632560 shares to 2099958 shares, the shareholding ratio was reduced from 5.626800% to 4.999990%, and the cumulative reduction ratio did not exceed 5% of the total share capital of the listed company. 3、 Basic information of this equity change
Information disclosure obligor’s reduction method reduction time reduction number of shares (shares) reduction proportion name type (%)
Shanghai LeYang Kairui enterprise centralized bidding, RMB Pu in December 2021
Business management partnership block trading 23 – 2022 general shares 2632602 0.626810 (limited partnership) January 11
As of the date of issuance of this report, LeYang Kairui holds 2099958 shares of the company, all of which are non tradable shares, accounting for 4.999990% of the total share capital of the listed company, and the shareholding ratio has been less than 5%. LeYang Kairui is no longer the major shareholder holding more than 5% of the company. 4、 There are restrictions on the rights of the shares in which the information disclosure obligor has interests in the listed company
The shares involved in this equity change are tradable shares with unlimited sales conditions, and there are no restrictions on the transfer of rights such as pledge and freezing.
All the shares involved in this equity change enjoy voting rights, and there are no rights restrictions or restricted transfers such as voting rights entrustment or restriction.
This change does not violate the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies and other laws and regulations, the business rules of the exchange and other relevant provisions and commitments.
Section V Trading of listed shares in the first six months
Except for the changes in equity disclosed this time, the information disclosure obligor did not buy or sell the shares of the listed company within 6 months before the signing date of this report.
Section VI other major matters
As of the signing date of this report, except for the matters contained in this report, the information disclosure obligor has no other information that must be disclosed to avoid misunderstanding of the contents of this report, as well as other information required by the CSRC or the stock exchange to be provided by the information disclosure obligor according to law.
Section VII statement of information disclosure obligor
I (and the organization I represent) promise that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
Information disclosure obligor: Shanghai LeYang Kairui enterprise management partnership (limited partnership) (seal) executive partner (signature): Wang Guangrong date: January 11, 2022
Section VIII documents for future reference
1、 Documents for future reference
(I) the business license of the information disclosure obligor;
(II) identification documents of the principal responsible person of the information disclosure obligor;
(III) this report signed by the information disclosure obligor. 2、 Location of documents for future reference
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Office of the board of directors.
Schedule
Simplified equity change report
Basic information
Name of listed company Jiangsu Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Co., Ltd. has No. 2, Liuzhuang Road, Hanjiang District, Yangzhou city where the listed company is located
Stock abbreviation Jiangsu Aidea Pharmaceutical Co.Ltd(688488) stock code 688488
Name of information disclosure obligor: Shanghai LeYang Kairui enterprise management information disclosure obligation: Shanghai Baoshan District Gaoyi road Chengli partnership (limited partner, room a1193, building 3, No. 112-118)
Increase □ decrease □ concerted action
The amount changes unchanged, but the shareholder changes \uf02a yes \uf02a no \uf02a
Chemical \uf02a
The obligor of information disclosure is the obligation of information disclosure
No is the first listed company yes \uf02a no □ whether the person is listed yes \uf02a no \uf02a
Actual control of major shareholder company
people
Centralized trading through stock exchange □ agreement transfer □
Method of equity change (administrative transfer or change of state-owned shares □ indirect transfer □
Multiple choice) acquisition of new shares issued by listed companies □ execution of court ruling □
Inheritance □ gift □
Others (block transactions)
Type of shares of information disclosure obligor: RMB common shares (A shares) number of shares with interests before disclosure: 23632560 shares and
